{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T20:47:25Z","timestamp":1740170845629,"version":"3.37.3"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"Special Issue_13","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Coronavirus disease (COVID) toes are pernio-like skin lesions associated with severe acute respiratory syndrome coronavirus 2. We observed pernio-like skin findings presenting after a Pfizer BioNTech vaccine, which significantly worsened after an infusion of rituximab. This suggests that the mechanism for COVID toes is interferon activation. Military providers may avoid unnecessary referrals for this self-limiting condition by anticipating this adverse effect.<\/jats:p>","DOI":"10.1093\/milmed\/usab314","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T18:54:09Z","timestamp":1632768849000},"page":"e1563-e1565","source":"Crossref","is-referenced-by-count":4,"title":["Post-vaccination COVID Toes (Chilblains) Exacerbated by Rituximab Infusion Suggests Interferon Activation as Mechanism"],"prefix":"10.1093","volume":"187","author":[{"given":"Jana W","family":"Qiao","sequence":"first","affiliation":[{"name":"Department of Family and Community Medicine, Penn State Health Milton S. Hershey , Hershey, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongwook","family":"Dan","sequence":"additional","affiliation":[{"name":"Penn State College of Medicine , Hershey, PA 17033, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6385-9128","authenticated-orcid":false,"given":"Michael E","family":"Wolf","sequence":"additional","affiliation":[{"name":"Division of Preventive, Occupational, and Aerospace Medicine, Mayo Clinic , Rochester, MN 55902, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M","family":"Zoccoli","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, Penn State Health Milton S. Hershey , Hershey, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore J","family":"Demetriou","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, Penn State Health Milton S. Hershey , Hershey, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-5890","authenticated-orcid":false,"given":"Robert P","family":"Lennon","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, Penn State College of Medicine , Hershey, PA 17033, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"issue":"3","key":"2022121510471507400_R1","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/j.jaad.2020.06.052","article-title":"When interferon tiptoes through COVID-19: pernio-like lesions and their prognostic implications during SARS-CoV-2 infection","volume":"83","author":"Damsky","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2022121510471507400_R2","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2020.05.109","article-title":"Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries","volume":"83","author":"Freeman","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2022121510471507400_R3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri3133","article-title":"Immunomodulatory functions of type I interferons","volume":"12","author":"Gonz\u00e1lez-Navajas","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"2022121510471507400_R4","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"4","key":"2022121510471507400_R5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","article-title":"Type I interferon in rheumatic diseases","volume":"14","author":"Muskardin","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"64","key":"2022121510471507400_R6","first-page":"229","article-title":"New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine","volume":"12","author":"Verweij","year":"2011","journal-title":"Discov Med"},{"author":"U.S. Food and Drug Administration release","key":"2022121510471507400_R7","article-title":"FDA issues emergency use authorization for third COVID-19 vaccine"},{"article-title":"Tracking COVID-19 vaccinations worldwide","volume-title":"CNN Health Website","author":"Pettersson","key":"2022121510471507400_R8"},{"author":"Shimabukuro","key":"2022121510471507400_R9","article-title":"COVID-19 vaccine safety update"},{"key":"2022121510471507400_R10","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taab024","article-title":"\u201cBlue toes\u201d following vaccination with the BNT162b2 mRNA COVID-19 vaccine","author":"Davido","year":"2021","journal-title":"J Travel Med"},{"issue":"4","key":"2022121510471507400_R11","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jaad.2020.06.1018","article-title":"New insights in COVID-19\u2013associated chilblains: a comparative study with chilblain lupus erythematosus","volume":"83","author":"Battesti","year":"2020","journal-title":"J Am Acad Dermatol"},{"author":"Fact Sheet for Recipients and Caregivers","key":"2022121510471507400_R12","article-title":"Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) in individuals 16 years of age or older"},{"key":"2022121510471507400_R13","article-title":"Entire force may be vaccinated for COVID-19 by early summer","volume-title":"DOD News","author":"Lopez","year":"2021"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/187\/Special%20Issue_13\/e1563\/47913773\/usab314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/187\/Special%20Issue_13\/e1563\/47913773\/usab314.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T21:58:11Z","timestamp":1671141491000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/187\/Special%20Issue_13\/e1563\/6376041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":13,"journal-issue":{"issue":"Special Issue_13","published-online":{"date-parts":[[2021,7,23]]},"published-print":{"date-parts":[[2022,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usab314","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"type":"print","value":"0026-4075"},{"type":"electronic","value":"1930-613X"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2021,7,23]]}}}